| Literature DB >> 29454352 |
Bo Yuan1, Yuantao Wang1, Jialin Gao1, Yongrui Zhang1, Yaowen Fu2, Wei An3.
Abstract
BACKGROUND: The objective of this study was to examine the effectiveness and safety of lower pole (LP) approach in retroperitoneal laparoscopic radical nephrectomy (LRN).Entities:
Keywords: Effectiveness; Lateroposterior space approach; Lower pole approach; Radical nephrectomy; Retroperitoneal laparoscopy; Safety
Mesh:
Year: 2018 PMID: 29454352 PMCID: PMC5816350 DOI: 10.1186/s12957-018-1324-7
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Positions of trocar ports in retroperitoneal laparoscopy (left panel, right-side laparoscopy; right panel, left-side laparoscopy)
Fig. 2Retroperitoneal laparoscopy for radical nephrectomy using the lower pole approach. A, Gerota’s fascia; B, peritoneum; C, psoas major; D, lateroposterior space; E, lateroanterior space; F, ureter; G, connective tissue; H, lumbar vein; I, renal vein; J, renal artery
Fig. 3Flow chart of treatment algorithm. RN, radical nephrectomy; LRN, laparoscopic radical nephrectomy; LP, lower pole; LPS, lateroposterior space
Baseline characteristics of patients (n = 132)
| LP group ( | LPS group ( | ||
|---|---|---|---|
| Age (mean ± SD, year) | 57.0 ± 2.1 | 57.1 ± 2.1 | 0.7884 |
| Sex (M:F) | 41/37 | 31/23 | 0.5990 |
| BMI (mean ± SD, kg/m2) | 27.0 ± 1.7 | 24.5 ± 1.5 | < 0.0001 |
| Size of tumor (mean ± SD, cm) | 6.9 ± 3.5 | 4.1 ± 3.3 | < 0.0001 |
| Location of tumor (%) | 0.0128 | ||
| Upper pole | 18 (23.1) | 15 (27.8) | 0.5471 |
| Medial part | 45 (57.7) | 20 (37.0) | 0.0223 |
| Lower pole | 15 (19.2) | 19 (35.2) | 0.0451 |
| Previous abdominal surgery (%) | 3 (3.8) | 1 (1.9) | 0.6443 |
| Concomitant conditions (%) | |||
| Hypertension | 20 (25.6) | 12 (22.2) | 0.6851 |
| Diabetes mellitus | 20 (25.6) | 10 (18.5) | 0.4014 |
| Cardiovascular diseases | 12 (15.4) | 15 (27.8) | 0.1234 |
Student’s t test was used to analyze the data
Note: LRN laparoscopic radical nephrectomy, LP lower pole, LPS lateroposterior space, BMI body mass index
Surgical outcomes of retroperitoneal LRN (n = 126) via LP approach compared to LPS approach (Student’s t test)
| LP group ( | LPS group ( | ||
|---|---|---|---|
| Operative duration (mean ± SD, min) | 125.2 ± 5.8 | 135.4 ± 11.9 | < 0.0001 |
| Volume of blood loss (mean ± SD, mL) | 135.3 ± 17.2 | 219.6 ± 30.9 | < 0.0001 |
| Volume of transfusion (mean ± SD, mL) | 55.6 ± 28.3 | 141.1 ± 50.4 | < 0.0001 |
| Drainage volume (mean ± SD, mL) | 225.8 ± 43.2 | 212.0 ± 22.4 | 0.0331 |
| Time to resume oral intake (mean ± SD, day) | 2.1 ± 0.3 | 1.8 ± 0.3 | < 0.0001 |
| Time to resume off-bed activities (mean ± SD, day) | 2.6 ± 0.2 | 2.3 ± 0.3 | < 0.0001 |
| Time of drain removal (mean ± SD, day) | 5.1 ± 0.6 | 4.4 ± 0.2 | < 0.0001 |
| Length of hospitalization (mean ± SD, day) | 10.7 ± 3.5 | 11.4 ± 2.8 | 0.2370 |
Note: LRN laparoscopic radical nephrectomy, LP lower pole, LPS lateroposterior space
Complications and morbidities (%) of patients scheduled for retroperitoneal LRN (n = 132) via LP approach compared to LPS approach (Student’s t test)
| LP group ( | LPS group ( | ||
|---|---|---|---|
| Abdominal organ injury | 1/78 (1.3%) | 1/54 (1.9%) | 1.0000 |
| Retroperitoneal hematoma | 1/78 (1.3%) | 2/54 (3.7%) | 0.5672 |
| Subcutaneous emphysema | 1/78 (1.3%) | 1/54 (1.9%) | 1.0000 |
| Injury of major vessels | 1/78 (1.3%) | 5/54 (9.3%) | 0.0416 |
| Conversion to open procedure | 1/78 (1.3%) | 4/54 (7.4%) | 0.0416 |
Note: LRN laparoscopic radical nephrectomy, LP lower pole, LPS lateroposterior space
Pathological outcomes of patients scheduled for retroperitoneal LRN (n = 132) via LP approach compared to LPS approach (Student’s t test)
| LP group ( | LPS group ( | ||
|---|---|---|---|
| Pathological type ( | 0.9910 | ||
| Clear cell | 56 (71.8%) | 38 (70.4%) | 1.0000 |
| Granular cell | 14 (17.9%) | 9 (16.7%) | 1.0000 |
| Papillary | 2 (2.6%) | 1 (1.9%) | 1.0000 |
| Chromophobe | 4 (5.1%) | 3 (5.6%) | 1.0000 |
| Others | 4 (5.1%) | 4 (7.4%) | 0.7156 |
| Metastatic | 3 (3.8%) | 1 (1.9%) | 0.6443 |
| Tumor staging ( | < 0.0001 | ||
| pT1a | 4 (6.4%) | 17 (31.5%) | < 0.0001 |
| pT1b | 9 (11.5%) | 6 (11.1%) | 1.0000 |
| pT2 | 31 (39.7%) | 25 (46.3%) | 0.4784 |
| pT3a | 30 (38.5%) | 6 (11.1%) | < 0.0001 |
| pT3b | 4 (5.1%) | 0 (0.0%) | 0.1442 |